>
Switch to:

Morphic Holding Operating Margin %

: -804.03% (As of Sep. 2021)
View and export this data going back to 2019. Start your Free Trial

Operating Margin % is calculated as Operating Income divided by its Revenue. Morphic Holding's Operating Income for the three months ended in Sep. 2021 was $-25.12 Mil. Morphic Holding's Revenue for the three months ended in Sep. 2021 was $3.12 Mil. Therefore, Morphic Holding's Operating Margin % for the quarter that ended in Sep. 2021 was -804.03%.

The historical rank and industry rank for Morphic Holding's Operating Margin % or its related term are showing as below:

NAS:MORF' s Operating Margin % Range Over the Past 10 Years
Min: -733.41   Med: -276.77   Max: -104.97
Current: -571.58

-733.41
-104.97

NAS:MORF's Operating Margin % is ranked lower than
64% of the 996 Companies
in the Biotechnology industry.

( Industry Median: -195.27 vs. NAS:MORF: -571.58 )

Morphic Holding's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Morphic Holding's Operating Income for the three months ended in Sep. 2021 was $-25.12 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2021 was $-92.24 Mil.


Morphic Holding Operating Margin % Historical Data

The historical data trend for Morphic Holding's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Morphic Holding Annual Data
Trend Dec17 Dec18 Dec19 Dec20
Operating Margin %
- -733.41 -276.77 -104.97

Morphic Holding Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Operating Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.44 -304.68 -652.40 -723.57 -804.03

Competitive Comparison

For the Biotechnology subindustry, Morphic Holding's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Morphic Holding Operating Margin % Distribution

For the Biotechnology industry and Healthcare sector, Morphic Holding's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Morphic Holding's Operating Margin % falls into.



Morphic Holding Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Morphic Holding's Operating Margin % for the fiscal year that ended in Dec. 2020 is calculated as

Operating Margin %=Operating Income (A: Dec. 2020 ) / Revenue (A: Dec. 2020 )
=-47.18 / 44.945
=-104.97 %

Morphic Holding's Operating Margin % for the quarter that ended in Sep. 2021 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2021 ) / Revenue (Q: Sep. 2021 )
=-25.118 / 3.124
=-804.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Morphic Holding  (NAS:MORF) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Morphic Holding Operating Margin % Related Terms

Thank you for viewing the detailed overview of Morphic Holding's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Morphic Holding Business Description

Morphic Holding logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
35 Gatehouse Drive, A2, Waltham, MA, USA, 02451
Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer.
Executives
Farrell Robert E Jr officer: SVP Finance and CAO CAMBRIDGE DISCOVERY PARK 100 ACORN PARK DRIVE, 5TH FLOOR CAMBRIDGE MA 02140
Lugovskoy Alexey officer: Chief Development Officer C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2 WALTHAM MA 02451
Devaul William officer: General Counsel and Secretary C/O MORPHIC HOLDING, INC. 35 GATEHOUSE DRIVE, A2 WALTHAM MA 02451
Slattery Joseph P director C/O TRANSENTERIX, INC. 635 DAVIS DRIVE, SUITE 300 MORRISVILLE NC 27560
Nashat Amir director 10835 ROAD TO THE CURE SUITE 205 SAN DIEGO CA 92121
Stampacchia Otello director 888 BOYLSTON ST., SUITE 1111 BOSTON MA 02199
Springer Timothy A director, 10 percent owner 36 WOODMAN ROAD CHESTNUT HILL MA 02467
Christensen Gustav director DYAX CORP. 300 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Bischofberger Norbert W director 333 LAKESIDE DR C/O GILEAD SCIENCES, INC. FOSTER CITY CA 94404
Goyal Vikas director C/O SR ONE, LTD., 161 WASHINGTON ST. SUITE 500, EIGHT TOWER BRIDGE CONSHOHOCKEN PA 19428
Rogers Bruce officer: Chief Scientific Officer C/O MORPHIC HOLDING, INC. 35 GATEHOUSE DRIVE, A2 WALTHAM MA 02451
Schegerin Marc officer: CFO and COO ARQULE INC 1 WALL ST FL6 BURLINGTON MA 01803
Linde Peter officer: Chief Medical Officer C/O MORPHIC HOLDING, INC. 35 GATEHOUSE DRIVE A2 WALTHAM ME 02451
Tipirneni Praveen P. director, officer: President and CEO C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2 WALTHAM MA 02451
Omega Fund V Gp, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111 BOSTON MA 02199

Morphic Holding Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)